Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS-NN/NN2 Vaccine With or Without Tdap in Healthy Non-pregnant Women
2023-508563-73-00Phase 3Authorised
- Sponsor
- MinervaX
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial of GBS-NN/NN2 vaccine in Streptococcus agalactiae infection (GBS) (4 arms), sponsored by MinervaX. Primary endpoints: Anti-tetanus toxoid seroprotection at Day 28 after third vaccination, Anti-diphtheria toxoid seroprotection at Day 28 after third vaccination and 8 more. Planned start Oct 2024; status: authorised.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on 2023-508563-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508563-73-00.